Flputnam Investment Management Co. Purchases 1,413 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Flputnam Investment Management Co. raised its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 4.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 36,158 shares of the medical research company's stock after buying an additional 1,413 shares during the period. Flputnam Investment Management Co.'s holdings in Thermo Fisher Scientific were worth $19,192,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of TMO. Savant Capital LLC grew its stake in Thermo Fisher Scientific by 0.5% during the fourth quarter. Savant Capital LLC now owns 3,627 shares of the medical research company's stock valued at $1,997,000 after acquiring an additional 18 shares in the last quarter. 1776 Wealth LLC grew its stake in Thermo Fisher Scientific by 2.4% in the 4th quarter. 1776 Wealth LLC now owns 799 shares of the medical research company's stock worth $440,000 after buying an additional 19 shares in the last quarter. Sugarloaf Wealth Management LLC grew its stake in Thermo Fisher Scientific by 6.9% in the 4th quarter. Sugarloaf Wealth Management LLC now owns 294 shares of the medical research company's stock worth $156,000 after buying an additional 19 shares in the last quarter. Rosenberg Matthew Hamilton grew its stake in Thermo Fisher Scientific by 3.7% in the 4th quarter. Rosenberg Matthew Hamilton now owns 526 shares of the medical research company's stock worth $279,000 after buying an additional 19 shares in the last quarter. Finally, Tsfg LLC grew its stake in Thermo Fisher Scientific by 8.3% in the 4th quarter. Tsfg LLC now owns 249 shares of the medical research company's stock worth $132,000 after buying an additional 19 shares in the last quarter. Institutional investors and hedge funds own 89.23% of the company's stock.

Thermo Fisher Scientific Stock Down 1.3 %

Shares of NYSE:TMO traded down $7.36 during midday trading on Monday, reaching $557.87. The company's stock had a trading volume of 1,031,012 shares, compared to its average volume of 1,546,595. The firm has a 50 day moving average of $571.79 and a 200-day moving average of $526.53. The firm has a market capitalization of $212.94 billion, a P/E ratio of 36.11, a PEG ratio of 2.38 and a beta of 0.80. The company has a quick ratio of 1.39, a current ratio of 1.75 and a debt-to-equity ratio of 0.67. Thermo Fisher Scientific Inc. has a 12-month low of $415.60 and a 12-month high of $603.82.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its earnings results on Wednesday, January 31st. The medical research company reported $5.67 earnings per share for the quarter, topping analysts' consensus estimates of $5.64 by $0.03. The firm had revenue of $10.89 billion for the quarter, compared to the consensus estimate of $10.73 billion. Thermo Fisher Scientific had a net margin of 13.99% and a return on equity of 18.78%. The company's revenue was down 4.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $5.40 EPS. On average, research analysts anticipate that Thermo Fisher Scientific Inc. will post 21.52 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, April 15th. Stockholders of record on Friday, March 15th will be given a $0.39 dividend. The ex-dividend date is Thursday, March 14th. This is an increase from Thermo Fisher Scientific's previous quarterly dividend of $0.35. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.28%. Thermo Fisher Scientific's dividend payout ratio is currently 10.10%.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on TMO shares. Raymond James boosted their price objective on shares of Thermo Fisher Scientific from $515.00 to $605.00 and gave the stock an "outperform" rating in a report on Thursday, February 1st. Citigroup assumed coverage on shares of Thermo Fisher Scientific in a report on Monday, March 18th. They set a "neutral" rating and a $620.00 price target for the company. The Goldman Sachs Group upped their price target on shares of Thermo Fisher Scientific from $550.00 to $640.00 and gave the company a "buy" rating in a report on Wednesday, April 10th. Evercore ISI upped their price target on shares of Thermo Fisher Scientific from $575.00 to $610.00 and gave the company an "outperform" rating in a report on Thursday, April 4th. Finally, Royal Bank of Canada upped their price target on shares of Thermo Fisher Scientific from $592.00 to $642.00 and gave the company an "outperform" rating in a report on Thursday, February 1st. Five analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $601.56.

Insider Activity at Thermo Fisher Scientific

In related news, Director Debora L. Spar sold 164 shares of the stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $546.97, for a total transaction of $89,703.08. Following the sale, the director now directly owns 1,207 shares of the company's stock, valued at approximately $660,192.79. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, Director Debora L. Spar sold 164 shares of the stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $546.97, for a total transaction of $89,703.08. Following the sale, the director now directly owns 1,207 shares of the company's stock, valued at approximately $660,192.79. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Marc N. Casper sold 5,547 shares of the stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $550.62, for a total transaction of $3,054,289.14. Following the sale, the chief executive officer now directly owns 43,608 shares in the company, valued at $24,011,436.96. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 50,277 shares of company stock valued at $28,513,384. 0.32% of the stock is owned by insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.